Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 11
Submit an article Journal homepage
150
Views
6
CrossRef citations to date
0
Altmetric
Reviews

A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies

Masahiko Yamamoto Nagoya University Graduate School of Medicine, Department of Neurology, Nagoya 466-8550, Aichi, Japan +81 52 744 2385; +81 52 744 2384; [email protected]; Aichi Gaguin University School of Health Science, Department of Speech Pathology and Audiology, Nisshin, Aichi, Japan
, MD,
Fumiaki Tanaka Nagoya University Graduate School of Medicine, Department of Neurology, Nagoya 466-8550, Aichi, Japan +81 52 744 2385; +81 52 744 2384; [email protected]
, MD,
Hiroshi Tatsumi Aichi Gaguin University School of Health Science, Department of Speech Pathology and Audiology, Nisshin, Aichi, Japan
, PhD &
Gen Sobue Nagoya University Graduate School of Medicine, Department of Neurology, Nagoya 466-8550, Aichi, Japan +81 52 744 2385; +81 52 744 2384; [email protected]
, MD
Pages 1845-1857 | Published online: 16 Jul 2008

Bibliography

  • Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998;24(2):104-17
  • Bunina TL. On intracellular inclusions in familial amyotrophic lateral sclerosis. Korsakov J Neuropath Psychiat 1962;62:1293-6
  • Okamoto K, Hirai S, Amari M, et al. Bunina bodies in amyotrophic lateral sclerosi immunostained with rabbit anti-cystatin C serum. Neurosci Lett 1993;162(1/2):125-8
  • Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2(11):806-19
  • Bergeron C. Oxidative stress: its role in the pathogenesis of amyotrophic lateral sclerosis. J Neurol Sci 1995;129(Suppl):81-4
  • Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001;27(4):257-74
  • Hand CK, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 2002;25(2):135-59
  • Ishigaki S, Liang Y, Yamamoto M, et al. X-Linked inhibitor of apoptosis protein is involved in mutant SOD1-mediated neuronal degeneration. J Neurochem 2002;82(3):576-84
  • Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature 2004;427(6977):801
  • Niwa J, Ishigaki S, Hishikawa N, et al. Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J Biol Chem 2002;277(39):36793-8
  • Hishikawa N, Niwa J, Doyu M, et al. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis. Am J Pathol 2003;163(2):609-19
  • Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 2004;75(6):933-47
  • Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Ann Rev Neurosci 2004;27:723-49
  • Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11(4):429-33
  • Traynor BJ, Bruijn L, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67(1):20-7
  • Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007;26(1):1-13
  • Broom WJ, Auwarter KE, Ni J, et al. Two approaches to drug discovery in SOD1-mediated ALS. J Biomol Screen 2006;11(7):729-35
  • Zoccolella S, Beghi E, Palagano G, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol 2007;14(3):262-8
  • Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;(1):CD001447
  • Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4(3):191-206
  • Mathie A, Veale EL. Therapeutic potential of neuronal two-pore domain potassium-channel modulators. Curr Opin Investig Drugs 2007;8(7):555-62
  • Kawahara Y, Sun H, Ito K, et al. Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neurosci Res 2006;54(1):11-4
  • Sun H, Kawahara Y, Ito K, et al. Slow and selective death of spinal motor neurons in vivo by intrathecal infusion of kainic acid: implications for AMPA receptor-mediated excitotoxicity in ALS. J Neurochem 2006;98(3):782-91
  • Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433(7021):73-7
  • Surtees R, Leonard J, Austin S. Association of demyelination with deficiency of cerebrospinal-fluid S-adenosylmethionine in inborn errors of methyl-transfer pathway. Lancet 1991;338(8782/8783):1550-4
  • Kikuchi M, Kashii S, Honda Y, et al. Protective effects of methylcobalamin, a vitamin B12 analog, against glutamate-induced neurotoxicity in retinal cell culture. Invest Ophthalmol Vis Sci 1997;38(5):848-54
  • Kaji R, Kodama M, Imamura A, et al. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve 1998;21(12):1775-8
  • Izumi Y, Kaji R. Clinical trials of ultra-high-dose methylcobalamin in ALS. Brain Nerve 2007;59(10):1141-7
  • Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39(2):147-57
  • Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 2005;112(5):649-60
  • Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5(3):347-50
  • Shefner JM, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in ALS. Neurology 2004;63(9):1656-61
  • Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 2002;36(4):455-60
  • Kaufmann P, Levy G, Montes J, et al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler 2007;8(1):42-6
  • Levy G, Kaufmann P, Buchsbaum R, et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006;66(5):660-3
  • Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 2006;7(1):70-80
  • Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006;22(1):40-9
  • Niyaz M, Numakawa T, Matsuki Y, et al. MCI-186 prevents brain tissue from neuronal damage in cerebral infarction through the activation of intracellular signaling. J Neurosci Res 2007;85(13):2933-42
  • Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 2006;7(4):241-5
  • Funakoshi H, Ohya W, Kadoyama K, Nakamura T. ALS and neurotrophic factors: HGF as a novel neurotrophic and neuroregenerative factor. Brain Nerve 2007;59(10):1195-202
  • Kato S, Funakoshi H, Nakamura T, et al. Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation. Acta Neuropathol 2003;106(2):112-20
  • Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J Neurosci 2002;22(15):6537-48
  • Ishigaki A, Aoki M, Nagai M, et al. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model. J Neuropathol Exp Neurol 2007;66(11):1037-44
  • Kadoyama K, Funakoshi H, Ohya W, Nakamura T. Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci Res 2007;59(4):446-56
  • Chen H, Tung YC, Li B, et al. Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging 2007;28(8):1148-62
  • Nagano I, Shiote M, Murakami T, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res 2005;27(7):768-72
  • Nagano I, Ilieva H, Shiote M, et al. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J Neurol Sci 2005;235(1/2):61-8
  • Messi ML, Clark HM, Prevette DM, et al. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS. Exp Neurol 2007;207(1):52-63
  • Ekestern E. Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener Dis 2004;1(2/3):88-100
  • Yamamoto M, Li M, Mitsuma N, et al. Preserved phosphorylation of RET receptor protein in spinal motor neurons of patients with amyotrophic lateral sclerosis: an immunohistochemical study by a phosphorylation-specific antibody at tyrosine 1062. Brain Res 2001;912(1):89-94
  • Yamamoto M, Mitsuma N, Ito Y, et al. Expression of GDNF receptor (RET and GDNFR-alpha) mRNAs in the spinal cord of patients with amyotrophic lateral sclerosis. Brain Res 1999;820(1/2):77-85
  • Yamamoto M, Sobue G, Yamamoto K, et al. Expression of glial cell line-derived growth factor mRNA in the spinal cord and muscle in amyotrophic lateral sclerosis. Neurosci Lett 1996;204(1/2):117-20
  • Yamamoto M, Kobayashi Y, Li M, et al. In vivo gene electroporation of glial cell line-derived neurotrophic factor (GDNF) into skeletal muscle of SOD1 mutant mice. Neurochem Res 2001;26(11):1201-7
  • Acsadi G, Anguelov RA, Yang H, et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Human Gene Ther 2002;13(9):1047-59
  • Suzuki M, McHugh J, Tork C, et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One 2007;2(1):e689
  • Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34(4):383-94
  • Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28(2):131-8
  • Zheng C, Sköld MK, Li J, et al. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem Biophys Res Commun 2007;363(4):989-93
  • Zheng C, Nennesmo I, Fadeel B, Henter JI. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2004;56(4):564-7
  • Wang Y, Mao XO, Xie L, et al. Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice. J Neurosci 2007;27(2):304-7
  • Chen W, Saeed M, Mao H, et al. Lack of association of VEGF promoter polymorphisms with sporadic ALS. Neurology 2006;67(3):508-10
  • MacGowan DJ, Scelsa SN, Imperato TE, et al. A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS. Neurology 2007;68(22):1944-6
  • Scelsa SN, MacGowan DJ, Mitsumoto H, et al. A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS. Neurology 2005;64(7):1298-300
  • Hara MR, Thomas B, Cascio MB, et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA 2006;103(10):3887-9
  • Groeneveld GJ, Van Muiswinkel FL, De Leeuw Van Weenen J, et al. CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(4):220-5
  • Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69(8):776-84
  • Olanow CW, Schapira AH, Lewitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5(12):1013-20
  • Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002;417(6884):74-8
  • Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002;10(3):268-78
  • Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6(12):1045-53
  • Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52(6):771-8
  • Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60(1):22-31
  • Shefner JM, Cudkowicz ME, Zhang H, et al.; Northeast ALS Consortium. Revised statistical motor unit number estimation in the Celecoxib/ALS trial. Muscle Nerve 2007;35(2):228-34
  • Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 2007;4(4):378-85
  • Yoshihara T, Ishigaki S, Yamamoto M, et al. Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 2002;80(1):158-67
  • Kiaei M, Petri S, Kipiani K, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26(9):2467-73
  • Habisch HJ, Schwalenstöcker B, Danzeisen R, et al. Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS. Exp Neurol 2007;206(2):288-95
  • Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Human Mol Genet 2004;13(11):1183-92
  • Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005;11(10):1088-95
  • Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93(5):1087-98
  • Kieran D, Kalmar B, Dick JR, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10(4):402-5
  • Cheung YK, Gordon PH, Levin B. Selecting promising ALS therapies in clinical trials. Neurology 2006;67(10):1748-51
  • Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC International Workshop. Amyotroph Lateral Scler 2007;8(4):217-23
  • Klivenyi P, Kiaei M, Gardian G, et al. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;88(3):576-82
  • Gordon PH, Cheng B, Montes J, et al. Outcome measures for early phase clinical trials. Amyotroph Lateral Scler 2007;8(5):270-3
  • Mitsumoto H, Ulug AM, Pullman SL, et al. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology 2007;68(17):1402-10
  • Cronin S, Greenway MJ, Ennis S, et al. Elevated serum angiogenin levels in ALS. Neurology 2006;67(10):1833-6
  • De Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119(3):497-503
  • Li M, Ona VO, Guégan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000;288(5464):335-9
  • Inoue H, Tsukita K, Iwasato T, et al. The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J 2003;22(24):6665-74
  • Przedborski S. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist 2004;10(1):1-7
  • Jiang YM, Yamamoto M, Tanaka F, et al. Gene expressions specifically detected in motor neurons (dynactin 1, early growth response 3, acetyl-CoA transporter, death receptor 5, and cyclin C) differentially correlate to pathologic markers in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2007;66(7):617-27
  • Jiang YM, Yamamoto M, Kobayashi Y, et al. Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 2005;57(2):236-51
  • Li L, Zhang X, Le W. Altered macroautophagy in the spinal cord of SOD1 mutant mice. Autophagy 2008;4(3):290-3
  • Filimonenko M, Stuffers S, Raiborg C, et al. Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. J Cell Biol 2007;179(3):485-500
  • Pramatarova A, Laganière J, Roussel J, et al. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci 2001;21(10):3369-74
  • Gong YH, Parsadanian AS, Andreeva A, et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci 2000;20(2):660-5
  • Jaarsma D, Teuling E, Haasdijk ED, et al. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J Neurosci 2008;28(9):2075-88
  • Boillée S, Yamanaka K, Lobsiger CS, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006;312(5778):1389-92
  • Yamanaka K, Chun SJ, Boillée S, et al. Astrocytes as determinants of disease progression in inherited amyotrophic sclerosis. Nat Neurosci 2008:11(3):251-3
  • Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: ‘prepare for the worst and hope for the best’. JAMA 2007;298(2):207-16
  • Brownlee A, Palovcak M. The role of augmentative communication devices in the medical management of ALS. NeuroRehabilitation 2007;22(6):445-50
  • Tanaka F, Niwa J, Ishigaki S, et al. Gene expression profiling toward understanding of ALS pathogenesis. Ann NY Acad Sci 2006;1086:1-10
  • Schymick JC, Talbot K, Traynor BJ. Genetics of sporadic amyotrophic lateral sclerosis. Human Mol Genet 2007;16:R233-42
  • Schymick JC, Scholz SW, Fung HC, et al. Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2007;6(4):322-8
  • Kasperaviciute D, Weale ME, Shianna KV, et al. Large-scale pathways-based association study in amyotrophic lateral sclerosis. Brain 2007;130(Part 9):2292-301
  • Dunckley T, Huentelman MJ, Craig DW, et al. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 2007;357(8):775-88
  • Van Es MA, Van Vught PW, Blauw HM, et al. ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol 2007;6(10):869-77
  • Van Es MA, Van Vught PW, Blauw HM, et al. Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet 2008;40(1):29-31
  • Gwinn K, Corriveau RA, Mitsumoto H, et al. Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. PLoS One 2007;2(12):e1254
  • Azzouz M. Gene therapy for ALS: progress and prospects. Biochim Biophys Acta 2006;1762(11/12):1122-7
  • Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301(5634):839-42
  • Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11(4):423-8
  • MacKenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61(5):427-34
  • Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116(8):2290-6
  • Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008;265(1/2):78-83
  • Habisch HJ, Janowski M, Binder D, et al. Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects. J Neural Transm 2007;114(11):1395-406
  • Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448(7151):313-7
  • Okano H. Stem cell biology of the central nervous system. J Neurosci Res 2002;69(6):698-707

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.